Regencell Bioscience (NASDAQ:RGC) Trading Down 6.6% – Time to Sell?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) fell 6.6% during mid-day trading on Friday . The company traded as low as $30.68 and last traded at $31.26. 61,975 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 635,571 shares. The stock had previously closed at $33.46.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Regencell Bioscience Price Performance

The company’s 50-day moving average is $28.08 and its two-hundred day moving average is $19.31.

Hedge Funds Weigh In On Regencell Bioscience

Several hedge funds and other institutional investors have recently made changes to their positions in RGC. Vident Advisory LLC increased its position in Regencell Bioscience by 65.7% in the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after acquiring an additional 11,866 shares during the period. Y Intercept Hong Kong Ltd bought a new position in shares of Regencell Bioscience in the second quarter worth $222,000. Hudson Bay Capital Management LP acquired a new position in shares of Regencell Bioscience during the fourth quarter valued at $275,000. XTX Topco Ltd bought a new stake in shares of Regencell Bioscience during the third quarter valued at about $598,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Regencell Bioscience during the second quarter valued at about $768,000. 0.13% of the stock is currently owned by institutional investors and hedge funds.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.